09.01.2012
JSC «Grindeks» informs that the Supervisory Council has appointed Mr. Juris Bundulis as Chairman of the Board of JSC «Grindeks».
Mr. Kirovs Lipmans, the Chairman of the Council of JSC
«Grindeks»: "Appointing Juris Bundulis to position of the
Chairman of the Board of «Grindeks», the Supervisory Council
took into account his competency, experience and
professionalism - he is knowledgeable in complex
pharmaceutical manufacturing processes, in particularities of
research projects, as well as in the business in general. I
would like to emphasize that Latvia as the sales market is
small for such a company as «Grindeks» - we are leading
pharmaceutical company in Baltic's with high international
recognition and reputation. Our business activities and
strategy have been export-oriented for long years. At present
the products of the company are exported to 50 countries
comprising 95% of the total turnover. For that reason,
increase of the sales volumes in export markets, enlargement
of product portfolio and enhancement of the competitiveness
of company will be the main tasks for the new Chairman of the
Board."
Juris Bundulis has obtained the Doctoral degree in Biological
Sciences in the University of Latvia; he has also graduated
from the Faculty of Chemistry of the University of Latvia.
Juris Bundulis has worked in «Grindeks» previously as the
Marketing and Sales director and the Scientific Research and
Development director. Prior his appointment as Chairman of
the Board of «Grindeks» Juris Bundulis was the Deputy State
Secretary of the Health Ministry of Latvia, where he worked
on health politics issues.
About «Grindeks»
«Grindeks» is the leading pharmaceutical company in the
Baltic States. Its main fields of action are: research,
development, manufacturing and sale of original products,
generics and active pharmaceutical ingredients. The Group of
«Grindeks» consists of four subsidiary companies in Latvia,
Estonia and Russia, as well representative offices in ten
countries.
«Grindeks» specializes in the heart and cardiovascular, CNS
and anti-cancer medication therapeutic groups. A range of
products covers a successful combination of original products
and generics, with the original products Mildronate® and
Ftorafur® and more than 100 forms of effective and safe
generics included therein. Currently «Grindeks» produces 16
active pharmaceutical ingredients.
Products of the company are exported to 50 countries and its
export comprises more than 95% of the total turnover. The
main markets are: Russia and other CIS countries, the Baltic
States, Germany and the Netherlands. In 2010 The Ministry of
Economics of Republic of Latvia and Investment and
Development Agency of Latvia awarded «Grindeks» as the most
export potential company of Latvia.
During the last years the company realized many considerable
investment projects in purpose to increase production
capacity and develop infrastructure and invested 32.7 million
lats within five years.
JSC «Grindeks» shares are listed in the Official List of
"NASDAQ OMX Riga". Major shareholders of JSC «Grindeks» are
Kirovs Lipmans - 33.29%, Anna Lipmane - 16.69%, "AB.LV
Private Equity fund 2010" - 11.38%, "Skandinaviska Enskilda
Banken" - 11.01%, "Swedbank" AS Clients Account -
9%.
Further information:
Laila K